Merck Expands Vaccine Access and Oncology Pipeline

Merck & Co., Inc. has made strides in both its vaccine and oncology portfolios, according to recent reports. The company's pneumococcal vaccine, CAPVAXIVE, is now included in Ontario's publicly funded adult immunization program. This expansion aims to increase access to the vaccine for a wider population.

In the realm of cancer treatment, Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR2015. This investigational drug is an oral inhibitor targeting the KRAS G12D mutation, a pathway implicated in various difficult-to-treat cancers. The acquisition signifies Merck's continued commitment to developing innovative oncology therapies.

Furthermore, coverage today notes that Merck and partner Daiichi Sankyo have decided to forgo seeking accelerated approval for their investigational lung cancer antibody-drug conjugate (ADC). The decision reflects a strategic shift in their regulatory approach for this specific therapy.

Merck is also positioned within the broader biotechnology landscape, with industry analysis highlighting its role in the growing cell line generation market. Reports project this market to reach $2.67 billion by 2032, fueled by advancements in AI, CRISPR, and automation, with Merck identified as a key innovator alongside other major industry players. Meanwhile, unrelated coverage discusses Moderna's stock performance and analyst commentary on the competitive landscape for AI-driven drug discovery.